Who are AMG820 and pembrolizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amg820-and-pembrolizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

AMG820 and pembrolizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AMG820 and pembrolizumab (AMG820 and pembrolizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor and CD28 antagonist. Area: Oncology.

phase 1 PD-1 inhibitor and CD28 antagonist PD-1 and CD28 Oncology Biologic Live · refreshed every 30 min

Target snapshot

AMG820 and pembrolizumab (AMG820 and pembrolizumab) — AmMax Bio, Inc.. AMG820 is a monoclonal antibody targeting CD28 and pembrolizumab is a monoclonal antibody targeting PD-1.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AMG820 and pembrolizumab TARGET	AMG820 and pembrolizumab	AmMax Bio, Inc.	phase 1	PD-1 inhibitor and CD28 antagonist	PD-1 and CD28

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor and CD28 antagonist class)

AmMax Bio, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMG820 and pembrolizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/amg820-and-pembrolizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab